Report: Opioid Prescriptions Falling; Out-of-Pocket Drug Costs Reach $58 Billion

Apr 19, 2018 - 03:21 PM
opioid-prescriptions-decline

The number of U.S. retail opioid prescriptions fell by 10.2% in 2017, including a 16.1% decline in high-dose prescriptions, according to a report released today by the IQVIA Institute for Human Data Science. The Centers for Disease Control and Prevention defines high-dose prescriptions as 90 morphine milligram equivalents or more per day. Total MME volume fell by 12%, or 23.3 billion, the largest annual drop in more than 25 years, according to the report. New opioid therapy starts fell 7.8%, while treatment starts for medication-assisted therapies nearly doubled to 82,000 prescriptions per month. The report also includes many other findings about drug spending, including that patients spent $57.8 billion in 2017 in out-of-pocket costs for medicines, including copays, coinsurance, payments during deductible phases of their insurance, or due to lack of insurance coverage.

Related News Articles

Headline
AHA responds to Medicare $2 Drug List Model request for information
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…
Headline
AHA podcast: Thinking Outside the Box to Reduce Behavioral Health Stigma and Disparities 
In this conversation, Matthew Hoag, director of integrated behavioral health at Denver Health, shares how the organization is innovating through integration to…
Headline
CMS releases RFI, sample list of prescription drugs that may be included under proposed Medicare $2 Drug List Model 
The Centers for Medicare & Medicaid Services Oct. 9 released a request for information and a sample list of prescription drugs it intends to include under…
Headline
Reminder: CMS hosting webinar Oct. 21 on price transparency machine-readable file 2025 requirements 
The Centers for Medicare & Medicaid Services Oct. 21 will host a webinar on meeting its new hospital price transparency requirements becoming effective Jan…
Headline
HHS issues final guidance for second cycle of drug price negotiations 
The Department of Health and Human Services Oct. 2 released final guidance detailing the process for the second cycle of negotiations under the Medicare Drug…
Headline
Medicare Advantage, prescription drug programs to remain stable for 2025 
The Centers for Medicare & Medicaid Services Sept. 27 announced that average premiums, benefits and plan choices for Medicare Advantage and Part D will…